Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

Clinical trial NCT05068232 · RECRUITING

Trial details

NCT number: NCT05068232
Sponsor: University of Chicago
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Small-cell Lung Cancer Extensive-stage Small-cell Lung Cancer Lung Cancer

Start date: 2022-08-19
Primary completion: 2027-10-01
Enrollment: 49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.